The Technical Analyst
Kronos Bio, Inc. [KRON]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kronos Bio, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.96% $1.030
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 61.90 mill |
| EPS: | -1.950 |
| P/E: | -0.530 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 60.10 mill |
| Avg Daily Volume: | 0.280 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.530 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.530 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.984 (-4.42%) $-0.0455 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.916 - 1.144 ( +/- 11.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-21 | Olek Elizabeth A | Sell | 7 368 | Common Stock |
| 2024-02-16 | Olek Elizabeth A | Sell | 0 | Common Stock |
| 2024-02-16 | Olek Elizabeth A | Sell | 89 120 | Stock Option (Right to Buy) |
| 2024-02-16 | Olek Elizabeth A | Sell | 145 795 | Stock Option (Right to Buy) |
| 2024-02-16 | Olek Elizabeth A | Sell | 87 500 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 45.88 |
| Last 97 transactions |
| Buy: 7 377 688 | Sell: 1 665 671 |
Forecast:
16:00 - $1.030
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.030
Forecast 2: 16:00 - $1.030
Forecast 3: 16:00 - $1.030
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.030 (-0.96% ) |
| Volume | 0.210 mill |
| Avg. Vol. | 0.280 mill |
| % of Avg. Vol | 74.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KRON
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Latest Press Releases
2024-03-21 07:05:00 - Press Release
Kronos Bio Reports Recent Business Progress And Fourth-quarter And Full-year 2023 Financial Results
Phase 1/2 study of kb-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025
2024-03-07 16:05:00 - Press Release
Kronos Bio Announces Restructuring To Focus Resources On Clinical Development With Extended Cash Runway
Company to assess kb-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025
2024-03-05 16:44:00 - Press Release
Kronos Bio To Present Three Posters At Aacr 2024 Annual Meeting
San mateo, calif. and cambridge, mass., march 05, 2024 (globe newswire) -- kronos bio, inc. (nasdaq: kron), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the american association for cancer research (aacr) annual meeting, being held from april 5-10, 2024 in san diego, california.
2024-02-27 16:05:00 - Press Release
Kronos Bio Announces Participation In 44th Annual Cowen Health Care Conference
San mateo, calif. and cambridge, mass., feb. 27, 2024 (globe newswire) -- kronos bio, inc. (nasdaq: kron), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th annual cowen health care conference, taking place march 4-6, 2024, in boston, massachusetts.
2024-01-25 08:00:00 - Press Release
Kronos Bio Implements New Leadership Structure To Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new executive leadership team company eliminates three executive officer roles and appoints new executive leadership team
Latest News
2024-03-27 13:01:14 - Zacks Investment Research
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-03-05 16:44:00 - GlobeNewsWire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
2023-12-04 08:00:00 - GlobeNewsWire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:00 a.m. ET.
2023-11-20 10:17:26 - PennyStocks
Best Penny Stocks To Buy This Week? 4 To Watch Now
Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.
2023-11-13 18:47:31 - Zacks Investment Research
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.57 per share a year ago.
2023-10-27 08:00:00 - GlobeNewsWire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting
2023-10-04 16:05:00 - GlobeNewsWire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope
2023-06-01 16:05:00 - GlobeNewsWire
Kronos Bio Announces Participation in Upcoming Investor Conferences
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
2023-05-10 18:59:34 - Zacks Investment Research
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.65 per share a year ago.
2023-01-09 09:02:59 - PennyStocks
5 Hot Penny Stocks To Watch This Week With Big News
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.